(University of Illinois at Chicago) Researchers at the University of Illinois at Chicago have demonstrated that magnetic nanoparticles can be used to ferry chemotherapy drugs into the spinal cord to treat hard-to-reach spinal tumors in an animal model. The unique delivery system represents a novel way to target chemotherapy drugs to spinal cancer cells, which are hard to reach because the drugs must cross the blood-brain barrier.

Related Links:

Authors: Jiang L, Chen S, Zhao D, Yan J, Chen J, Yang C, Zheng G
Abstract
Glioma is the most common type of malignant intracranial tumor in adults and is associated with the highest mortality rate. Although surgery, radiotherapy, chemotherapy and other treatment methods have progressed, the median survival of patients with glioma is only 14‑15 months. Glioma cells are able to penetrate along blood vessels and invade into the surrounding normal brain tissue so that an overall resection of the tumor cannot be performed. In the process of metastasis, the resistance of cancer cells to anoikis has an important ro…

Abstract
BACKGROUND: The purpose of the current study is to investigate the impact of baseline characteristics on the outcomes of extensive-stage small cell lung cancer (SCLC) patients recruited into a clinical trial.
METHODS: This is a secondary analysis of the control arm (etoposide/carboplatin arm) of the “NCT00363415″ study which is a phase III study conducted between 2006 and 2007. Univariate analysis of factors affecting overall and progression-free survival was conducted through Cox regression analysis [including age, race, gender, ECOG performance score, body mass index, LDH, number of meta…

Source: Clinical Lung CancerCategory: Cancer & Oncology Authors: Tags: Clin Respir J Source Type: research

ConclusionsAtezolizumab was safe and well tolerated in this group of patients with recurrent glioblastoma. Our preliminary findings suggest that biomarkers, including peripheral CD4+  T cells and hypermutated tumor status, may help guide selection of patients with recurrent glioblastoma who might receive most benefit from atezolizumab therapy, supporting further atezolizumab combination studies in glioblastoma.

(Natural News) Roughly sixty percent of all brain cancer are gliomas, a tumor that starts in the glial cells of the brain or the spine. There are many different grades of gliomas; each describing a variance in growth potential and aggressiveness. Regardless, conventional therapies involving radiation and chemotherapy drugs have been shown to be inconsistent…

Source: NaturalNews.comCategory: Consumer Health News Source Type: news

Epithelial-to-mesenchymal transition (EMT) plays an important role in invasion and metastasis of various cancers including gliomas. EMT has also been linked to cancer stem cells and resistance to chemotherapy. An initial in-silico data mining in a published ependymoma (EPN) patient series (GSE21687) revealed upregulation of EMT-Transcription factors (EMT-TFs) in tumor samples. Further, quantitative real-time polymerase chain reaction (q-RT-PCR) based gene expression analysis of EMT-TFs in 96 EPNs showed significant up-regulation of SNAI1, SNAI2, ZEB1, and TWIST1 as compared to normal brain, associated with upregulation of …

Source: Human PathologyCategory: Pathology Authors: Tags: Original contribution Source Type: research

CONCLUSION: Multiple ALL chemotherapy agents can affect postnatal brain development or heart function. This study provides a ranking of agents based on potential toxicity, and thus highlights a subset likely to cause side effects in early adulthood for further study.
PMID: 30054283 [PubMed – as supplied by publisher]

Source: Clinical Cancer ResearchCategory: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research

CONCLUSION: Our anecdotal experience suggests that eribulin may have a potentially beneficial effect on brain metastases while maintaining a good systemic control of the disease in patients with MBC.
PMID: 30041177 [PubMed – in process]

Source: OncologyCategory: Cancer & Oncology Authors: Tags: Oncology Source Type: research

Internal documents from IBM Watson Health (NYSE:IBM) indicate that the company’s Watson for Oncology product often returns “multiple examples of unsafe and incorrect treatment recommendations,” according to a new report from STAT News.
The documents come from slides presented last year by IBM Watson Health’s deputy chief health officer, according to the report, and include feedback from customers that indicated the product is “often inaccurate” and that its recommendations bring to light “serious questions about the process for building content and the underlying technology.&r…

Source: Mass DeviceCategory: Medical Devices Authors: Tags: Oncology Software / IT IBM Watson Health Source Type: news

Conclusion: Our anecdotal experience suggests that eribulin may have a potentially beneficial effect on brain metastases while maintaining a good systemic control of the disease in patients with MBC.Oncology 2018;94(suppl 1):29 –33

Source: OncologyCategory: Cancer & Oncology Source Type: research

Glioblastoma is one of the most lethal human cancers, with poor survival despite surgery, radiation treatment, and chemotherapy. Advances in the treatment of this type of brain tumor are limited because of several resistance mechanisms. Such mechanisms involve limited drug entry into the central nervous system compartment by the blood –brain barrier and by actions of the normal brain to counteract tumor-targeting medications. In addition, the vast heterogeneity in glioblastoma contributes to significant therapeutic resistance by preventing adequate control of the entire tumor mass by a single drug and by facilitating…

Source: World NeurosurgeryCategory: Neurosurgery Authors: Tags: From the Annals of Weill Cornell Neurological Surgery Source Type: research





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image